Scott D E, Golding H, Huang L Y, Inman J, Golding B
Laboratory of Plasma Derivatives, Division of Hematology, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Bethesda, Maryland 20892, USA.
AIDS Res Hum Retroviruses. 1998 Sep 20;14(14):1263-9. doi: 10.1089/aid.1998.14.1263.
Enhancement of immunity in the setting of HIV infection is difficult owing to loss of functional CD4+ T cells. The MHC class II-deficient mouse (II-/-) environment simulates that of the immunocompromised HIV-infected individual, since these mice have low CD4+ T cell numbers, defective CD4-dependent responses, and are susceptible to opportunistic infection. This strain was used to test whether heat-killed Brucella abortus (BA), covalently conjugated to the V3 peptide of HIV-1 (MN), could elicit anti-HIV responses. V3-BA, but not the T-dependent antigen V3-KLH, induced high levels of IL-12, IFN-gamma, and IL-10 mRNA in both wild-type (WT) and II-/- mice within 24 hr of injection. V3-BA-treated, but not V3-KLH-treated, II-/- mice developed serum IgG and IgA anti-V3 antibodies, with IgG2b and IgG3 as the predominant isotype. Viral neutralization studies, using a syncytium inhibition assay, demonstrated that the antibodies generated by V3-BA in II-/- mice were capable of neutralizing HIV. These experiments demonstrate that a heat-inactivated bacterium such as BA, when used as a carrier, can generate a cytokine environment that results in the production of neutralizing antiviral antibodies in an immunodeficient host. Such strategies could be important in the development of immunotherapies and vaccines for HIV-1 patients.
由于功能性CD4 + T细胞的丧失,在HIV感染情况下增强免疫力很困难。MHC II类缺陷小鼠(II - / - )的环境模拟了免疫受损的HIV感染个体的环境,因为这些小鼠的CD4 + T细胞数量低,CD4依赖性反应有缺陷,并且易受机会性感染。该品系用于测试与HIV-1(MN)的V3肽共价结合的热灭活布鲁氏菌(BA)是否能引发抗HIV反应。在注射后24小时内,V3 - BA而非T依赖性抗原V3 - KLH在野生型(WT)和II - / - 小鼠中均诱导了高水平的IL - 12、IFN - γ和IL - 10 mRNA。V3 - BA处理而非V3 - KLH处理的II - / - 小鼠产生了血清IgG和IgA抗V3抗体,其中IgG2b和IgG3为主要亚型。使用合胞体抑制试验进行的病毒中和研究表明,V3 - BA在II - / - 小鼠中产生的抗体能够中和HIV。这些实验表明,热灭活细菌如BA用作载体时,可以产生一种细胞因子环境,从而在免疫缺陷宿主中产生中和抗病毒抗体。这种策略在开发针对HIV - 1患者的免疫疗法和疫苗方面可能很重要。